Friday, April 11, 2014

MCM2 urine cytology for bladder cancer diagnosis


Cytosystems will be represented at EAU 2014 in Stockholm, presenting the clinical data on the use of MCM2 as cytology biomarker to diagnose Bladder Cancer and monitor for its recurrence. 

Poster session 51 Poster entitled “The combination of urine Pap cytology with immunocytochemical detection of minichromosome maintenance protein 2 (MCM-2) in patients with visible haematuria identifies most bladder cancers” on Sunday 13 April 2014. 

If you wish to discuss this in more detail, our most recent results or the instrumentation developed to facilitate this significant improvement in cytology one of our CRA representatives and clinical colleagues will be present. To arrange a meeting during or after the conference please contact us by emailing info@cytosystems.com 
www.cytosystems.com

Reply:

0 Comments:

Post a Comment

Twitter Delicious Facebook Digg Stumbleupon Favorites More

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Bluehost Review